GLP-1 Drugs Linked to Small but Real Increases in Smell and Taste Disturbances
A large EHR analysis finds GLP-1 users face a 48% higher relative risk of sensory disturbances — though absolute increases remain tiny.
Summary
GLP-1 receptor agonists — popular drugs for type 2 diabetes and obesity — may slightly raise the risk of smell and taste disturbances, according to a new analysis of electronic health records. Researchers compared adults with type 2 diabetes on GLP-1 medications against matched patients on other diabetes drugs over two years. GLP-1 users showed a 48% higher relative risk for combined smell and taste issues, including anosmia, parosmia, and parageusia. However, the absolute risk increases were very small — around 0.07–0.08%. Scientists believe GLP-1 receptors present in the olfactory bulb and taste buds may be involved. Importantly, smell loss is also a known early marker for Parkinson's and Alzheimer's disease, adding neurological relevance to these findings.
Detailed Summary
GLP-1 receptor agonists have transformed treatment of type 2 diabetes and obesity, but a new study raises questions about their effects on chemosensory function — specifically, the ability to smell and taste. Published in JAMA Otolaryngology-Head and Neck Surgery, the analysis used electronic health record data to compare adults with type 2 diabetes taking GLP-1 drugs against matched controls on other antidiabetic medications over a two-year follow-up period.
The headline finding: GLP-1 users had a 48% higher relative risk of combined smell and taste disturbances (HR 1.48, 95% CI 1.37–1.61). Breaking that down, smell disturbances — including anosmia and parosmia — carried an 81% higher relative risk, while taste disturbances such as parageusia showed a 52% higher relative risk. Despite these striking relative numbers, the absolute risk increases were very small, at approximately 0.08% and 0.07% respectively.
The biological rationale is plausible. GLP-1 receptors are found not only in the pancreas but also in the olfactory bulb and taste buds, suggesting these drugs could directly influence sensory processing pathways. Researchers noted the findings align with recent case reports implicating GLP-1 drugs — rather than underlying diabetic neuropathy alone — in sensory dysfunction.
The longevity angle adds urgency. Commentary authors from Boston University and the Ochsner Clinic Foundation highlighted that olfactory dysfunction is one of the most reliable early warning signs of neurodegenerative diseases, including Parkinson's and Alzheimer's. This means monitoring smell and taste in GLP-1 users could serve a broader neurological surveillance function.
Clinicians are advised to assess baseline sensory ability before prescribing GLP-1 agents and to weigh benefits against risks. For patients with severe obesity or cardiovascular disease, the drugs' proven benefits likely outweigh these small sensory risks. Still, ongoing surveillance and patient counseling are warranted as GLP-1 use continues to expand globally.
Key Findings
- GLP-1 users had a 48% higher relative risk of smell and taste disturbances vs. other diabetes drug users over 2 years.
- Absolute risk increases were very small: ~0.08% for smell and ~0.07% for taste disturbances.
- GLP-1 receptors are present in the olfactory bulb and taste buds, providing a plausible biological mechanism.
- Olfactory dysfunction is a known early marker for Parkinson's and Alzheimer's disease, raising neurological surveillance concerns.
- Clinicians should assess baseline sensory function before prescribing GLP-1 drugs and counsel patients on this risk.
Methodology
This is a news report summarizing a retrospective cohort study published in JAMA Otolaryngology-Head and Neck Surgery, a peer-reviewed journal. The study used electronic health record data with ICD code-based outcome identification, which relies on patient-reported symptoms rather than objective sensory testing. The source, MedPage Today, is a credible medical news outlet targeting clinicians.
Study Limitations
Outcomes were identified using ICD codes based on patient-reported symptoms, not validated objective sensory tests, which may introduce reporting bias. The study population was limited to adults with type 2 diabetes, limiting generalizability to people using GLP-1 drugs solely for weight loss. Absolute risk increases are very small, and causal mechanisms have not been definitively established.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: